FOXP3⁺ T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF𝜶 Agents

Table 4

Concomitant medications at baseline: comparison among studies on peripheral blood Treg frequencies in inflammatory bowel diseases.

Authors	Steroids	IM	Steroids + IM
Guidi et al.	34%	28%	None
Di Sabatino et al. [22]	NA	Discontinued 6 months before the study	NA
Li et al. [21]	20%	42.5%	27.5%
Boschetti et al. [23]	56%	63% (CD), 33% (UC)	NA

IM: immunomodulators; CD: Crohn’s disease; UC: ulcerative colitis; NA: not applicable.